Olivary hypertrophy improved by steroid treatment: Two case reports with unique presentations.

Anti-NMDA receptor antibody Autoimmune encephalitis CLIPPERS Guillain-Mollaret triangle Hypertrophic olivary degeneration Olivary hypertrophy

Journal

Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498

Informations de publication

Date de publication:
15 09 2019
Historique:
received: 19 03 2019
revised: 04 07 2019
accepted: 04 07 2019
pubmed: 16 7 2019
medline: 12 6 2020
entrez: 16 7 2019
Statut: ppublish

Résumé

Olivary hypertrophy (OH) is the secondary degeneration of the inferior olivary nucleus (ION). It is observed one month after the onset of a primary lesion within the dento-rubro-olivary pathway and is usually associated with oculopalatal tremors. Here, we report two unique cases with rare autoimmune diseases leading to OH development with progressive cerebellar ataxia, both of which improved with steroid treatment. The first patient was a 59-year-old man with slowly progressive dysarthria and ataxic gait without palatal tremor. Anti-N-methyl-d-aspartate (NMDA) receptor antibody was positive in the CSF, supporting a diagnosis of anti-NMDA receptor encephalitis. The second patient was a 56-year-old man who developed dysarthria, ataxia, gait disturbance, and palatal tremor. He was diagnosed with chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS), based on presence of a punctate contrast-enhancing lesion in the middle cerebellar peduncle, pons, and cerebellum on magnetic resonance imaging (MRI). Brain MRI in both patients demonstrated high signal intensity regions in the bilateral IONs. Semi-quantitative volume analysis of MRI revealed significant reduction in ION volume after steroid treatment and accordingly cerebellar ataxia was improved in both cases. Clinical and radiological features of the two cases were unique, indicating potential novel etiologies in the pathophysiology of OH associated with cerebellar ataxia.

Identifiants

pubmed: 31306854
pii: S0165-5728(19)30129-8
doi: 10.1016/j.jneuroim.2019.577003
pii:
doi:

Substances chimiques

Glucocorticoids 0
Prednisolone 9PHQ9Y1OLM

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

577003

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Masahiro Ohara (M)

Department of Neurology and Neurological Science, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Japan. Electronic address: oharnuro@tmd.ac.jp.

Nobuo Sanjo (N)

Department of Neurology and Neurological Science, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Japan. Electronic address: n-sanjo.nuro@tmd.ac.jp.

Takaaki Hattori (T)

Department of Neurology and Neurological Science, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Japan. Electronic address: takaaki-hattori@umin.ac.jp.

Jun Oyama (J)

Department of Diagnostic Radiology and Nuclear Medicine, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Japan. Electronic address: ooymmrad@tmd.ac.jp.

Meiko Hamada (M)

Department of Neurology and Neurological Science, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Japan; Department of Neurology, Ome Municipal General Hospital, Japan.

Kokoro Ozaki (K)

Department of Neurology and Neurological Science, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Japan; Diagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Japan. Electronic address: k-oznuro@tmd.ac.jp.

Takanori Yokota (T)

Department of Neurology and Neurological Science, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Japan. Electronic address: yokonuro@tmd.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH